# US 11,110,167 B2 · Vaccine adjuvant composition comprising inulin particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,167 B2
- Document ID: US11110167B2
- Status: Granted
- Kind: B2
- Application number: 15/597,371
- Filed: 2017-05-17
- Published: 2018-06-21
- Granted: 2021-09-07
- Earliest claimed: 2011-06-18
- Assignees: Vaxine Pty Ltd
- Applicants: Nikolai Petrovsky
- Inventors: Nikolai Petrovsky
- Web page: https://patentgrep.com/patent/US11110167B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/205: Rhabdoviridae, e.g. rabies virus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61K 39/35: Allergens
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55583: {Polysaccharides}
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a pharmaceutically acceptable composition comprising: particles of inulin; a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), and an antigen for use inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.

## Claims

### Claim 1

A immunogenic vaccine composition comprising:
(a) manufactured particles of delta inulin;
(b) a synthetic substance comprising one or more, but no greater than ten distinct molecular species of pathogen-associated molecular pattern (PAMP); and
(c) an antigen.

### Claim 2 (depends on 1)

The vaccine composition of claim 1 wherein the synthetic substance comprising or consisting of a PAMP comprises or consists of a substance that is selected from the group consisting of an agonist of one or more of a Toll-like receptor (TLR), a RIG ligase, a NOD-like receptor, a RNA helicase receptor, or a NALP.

### Claim 3 (depends on 1)

The vaccine composition of claim 1 wherein the synthetic substance comprising or consisting of a PAMP consists of a substance that is selected from the group consisting of lipoteichoic acid, RNA, DNA, oligonucleotide, and an unmethylated polynucleotide molecule.

### Claim 4 (depends on 1)

A The vaccine composition of claim 1 wherein the vaccine composition further comprises an antigen-binding carrier material.

### Claim 5 (depends on 1)

The vaccine composition of claim 1 wherein the antigen Is selected from the group comprising influenza virus, hepatitis B virus, rabies virus antigens iii a coronavirus from the family of Coronaviridae.

### Claim 6 (depends on 1)

The vaccine composition of claim 1 wherein the synthetic substance comprising a PAMP is a synthetic CG-motif containing oligonucleotide.

### Claim 7 (depends on 1)

The vaccine composition of claim 1 wherein the antigen is selected from the group of a protein, peptide, polysaccharide, lipid, allergen, polynucleotide molecule, polynucleotide molecule encoding an antigenic peptide or protein, viral vector, microorganism, parasite, bacterium and a virus.